MetaStat, Inc. engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Boston, Massachusetts. The company went IPO on 2008-02-13. The firm's therapeutic focus targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. The firm's product development programs are focused on developing drug candidates and companion diagnostic tests that target the MENA pathway. Its pipelines include MENA Diagnostic Assay and MetaSite Breast Assay. The MENA diagnostic assay is a tissue-based quantitative immunofluorescence (QIF) test that measures expression of the pro-metastatic MENA protein splice-variant which is associated with poor outcomes and metastasis in early-stage breast cancer (ESBC) and squamous cell carcinoma of the Lung. MetaSite Breast is an immunohistochemistry test (IHC) that measures micro-anatomical intravasation sites (TMEM) at blood vessels within the tumor microenvironment which are clinically validated as prognostic markers of metastasis in hormone receptor-positive (HR+) ESBC.
Follow-Up Questions
Qui est le CEO de MetaStat Inc ?
Mr. Douglas Hamilton est le President de MetaStat Inc, il a rejoint l'entreprise depuis 2015.
Quelle est la performance du prix de l'action MTST ?
Le prix actuel de MTST est de $0, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de MetaStat Inc ?
MetaStat Inc appartient à l'industrie Life Sciences Tools & Services et le secteur est Health Care
Quelle est la capitalisation boursière de MetaStat Inc ?
La capitalisation boursière actuelle de MetaStat Inc est de $0
